| 5-fluorouracil / Generic mfg. |
| Not yet recruiting | 3 | 100 | | | Epworth HealthCare, Epworth HealthCare | Pancreatic cancer | | | | |
ACTRN12609000642280: The effect of Taxotere, Cisplatin and 5-Fluorouracil (TPF) induction chemotherapy on intratumoral hypoxia in advanced head and neck squamous cell cancer |
|
|
| Recruiting | 3 | 25 | | | Peter MacCallum Cancer Centre, Sanofi Aventis | advanced head and neck squamous cell cancer | | | | |
JCOG1109, jRCTs031180202: A randomized controlled phase III comparing CF versus DCF versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancer |
|
|
| Completed | 3 | 600 | Japan | cisplatin - Generic mfg., docetaxel - Generic mfg., 5-fluorouracil - Generic mfg. | | stage IB/II/III thoracic esophageal cancer | | | | |
SHR-A1811-309, CTR20234257: A randomized, open-label, active-controlled, multicenter phase III clinical study of SHR-A1811 for injection versus investigator-selected treatment regimen in patients with advanced colorectal cancer who have failed treatment with oxaliplatin, fluorouraci |
|
|
| Ongoing | 3 | 120 | China | trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma, Lonsurf (trifluridine/tipiracil) - Servier, Otsuka, Stivarga (regorafenib) - Bayer, Fruzaqla (fruquintinib) - Takeda | Shanghai Hengrui Pharmaceutical Co., Ltd./ Jiangsu Hengrui Pharmaceutical Co., Ltd./ Suzhou Shengdia Biopharmaceutical Co., Ltd | Colorectal cancer | | | | |
ChiCTR-TRC-12002734: S-1 plus oxaliplatin (SOX) versus fluorouracil and folinic acid plus oxaliplatin (mFOLFOX6) for first-line treatment of patients with metastatic colorectal cancer: a randomised controlled trial |
|
|
| Completed | 3 | 360 | | S-1 plus oxaliplatin ;fluorouracil and folinic acid plus oxaliplatin | West China Hospital, Sichuan University; Shandong New Time（age） Pharmaceutical Co., LTD, Shandong New Time (age) Pharmaceutical Co., LTD | Shandong New Time (age) Pharmaceutical Co., LTD | | | | |
GIM2, NCT00433420: Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer |
|
|
| Active, not recruiting | 3 | 2000 | NA | pegfilgrastim, cyclophosphamide, epirubicin hydrochloride, fluorouracil, paclitaxel, adjuvant therapy | IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Gruppo Italiano Mammella (GIM) | Breast Cancer | 05/06 | 12/25 | | |
ChiCTR-TRC-08000061: Randomized controlled trial on the treatment of advanced gastric cancer by POF and IF regimes |
|
|
| Recruiting | 3 | 200 | | Irinotecan 80 mg/m2 ivgtt. for 30 minutes, formyltetrahydrofolate 500 mg/m2 ivgtt. for 2 hours; and then use fluorouracil 2000 mg/m2 ivgtt. for 22 hours. The treatment is given once a week for 6 weeks and repeated after a week's interval. ;Taxol 135 mg/m2 ivgtt. for 3 hours; then use formyltetrahydrofolate 400 mg/m2 ivgtt. for 2 hours and oxaliplatin 85 mg/m2 ivgtt. for 2 hours; and then use fluorouracil 2400 mg/m2 ivgtt. for 46 hours. One treatment cycle lasts 14 days. | Fujian Provincial Tumor Hospital; Fujian Anti-cancer Association, Fujian Anti-cancer Association | Gastric Cancer | | | | |
2010-023195-22: Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer(T = taxane, P = cisplatin, F = 5-fluorouracil) |
|
|
| Ongoing | 3 | 50 | Europe | Docetaxel, Cisplatin, Fluorouracil, Concentrate for solution for infusion, Docetaxel, Cisplatin, Fluorouracil | University of Liverpool, Aintree University Hospitals NHS Foundation Trust | Head and Neck Squamous Cell Carcinoma, in any of the following sites:- Lip / Oral Cavity- Paranasal / Nasal- Larynx- Hypopharynx- Cervical Osephagus- Oropharynx (HPV - ve) | | | | |
NCT00705068: Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial) |
|
|
| Active, not recruiting | 3 | 330 | US | carboplatin, cisplatin, docetaxel, fluorouracil, radiation therapy | University of Medicine and Dentistry New Jersey, Dana-Farber Cancer Institute | Head and Neck Cancer | 12/11 | | | |
2011-004406-25: Etude randomisée de phase III comparant une radiochimiothérapie préopératoire à une chimiothérapie néoadjuvante Folfirinox suivie de radiochimiothérapie préopératoire pour les patients atteints de cancers du rectum localement avancés (étude PRODIGE-GERCOR-SFRO-GRECCAR) |
|
|
| Not yet recruiting | 3 | 460 | Europe | OXALIPLATINE, IRINOTECAN, ACIDE FOLINIQUE, 5-FLUOROURACILE, Solution for injection/concentrate for solution for infusion, Powder and solution for solution for injection, ELOXATINE, CAMPTO, ELVORINE, 5-FLUOROURACIL | UNICANCER, PHRC | Adénocarcinome du rectum, Cancer du rectum, Diseases [C] - Cancer [C04] | | | | |
2012-000576-42: S1007 is a clinical trial for patients with node positive (1-3 positive nodes) Hormone Receptor-Positive and HER2-Negative Breast Cancer who when tested with the Oncotype DX test are shown to have a recurrence Score (RS) of 25 or Less. Patients will be randomised to receive endocrinetherapy +/- chemotherapy. |
|
|
| Ongoing | 3 | 5000 | Europe | Docetaxel, Cyclophosphamide, 5-FU, doxorubicin, Epirubicin, Paclitaxel, Tamoxifen, Concentrate for solution for infusion, Powder and solution for solution for injection, Injection, Solution for injection/infusion, Powder for solution for infusion, Tablet, Tamoxifen | Cancer Trials Ireland, Genomic Health | Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less, Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less, Diseases [C] - Cancer [C04] | | | | |
2011-005003-32: A study comparing the effect of chemotherapy with the effect of chemotherapy plus local removal of metastases for patients with cancer of the large bowel which has spread to multiple organs. |
|
|
| Ongoing | 3 | 478 | Europe | capecitabin, oxaliplatin, bevacizumab, fluorouracil, Folinic acid, Film-coated tablet, Concentrate for solution for infusion, Concentrate for solution for injection/infusion, Solution for injection/infusion, Xeloda, Eloxatin, Avastin, Fluorouracil, Sodiofolin | VU University Medical Center, Department of Medical Oncology, VU University Medical Center, Department of Medical Oncology | multi-organ metastatic colorectal cancer, Patients with metastases of large bowel cancer in multiple organs, Diseases [C] - Cancer [C04] | | | | |
2012-005748-12: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study INTERET DE LA CHIMIOHYPERTHERMIE INTRAPERITONEALE (CHIP) ADJUVANTE A L’OXALIPLATINE DANS LE TRAITEMENT CURATIF DES CANCERS GASTRIQUES AVANCES. ETUDE NATIONALE, RANDOMISEE ET MULTICENTRIQUE DE PHASE III. |
|
|
| Ongoing | 3 | 322 | Europe | 5 Fluorouracilo, L01B1A, Solution for injection/infusion, Oxaliplatin, 5 Fluorouracilo, Levofolinate Calcium | Hospices Civils de Lyon, Ministère de la Santé, Hospices Civils de Lyon | Gastric adenocarcinoma, Stomach cancer, Diseases [C] - Digestive System Diseases [C06] | | | | |
2013-001863-21: Optimizing neoadjuvant systemic treatment in HER2 positive breast cancer - the TRAIN-2 study |
|
|
| Ongoing | 3 | 394 | Europe | Herceptin, Carboplatine Sandoz, Taxol, Endoxan, 5-Fluorouracil Sandoz, Epirubicine HCl Sandoz, Perjeta, Concentrate for solution for infusion, Powder for solution for infusion, Solution for infusion, Herceptin, Carboplatine Sandoz, Taxol, Endoxan, 5-Fluorouracil Sandoz, Epirubicine HCl Sandoz, Perjeta | BOOG Study Center, Roche | Breast cancer, HER2 positive, stage II or III, Breast cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-12002782: Compare single intensity-modulated radiotherapy to concurrent chemoradiotherapy in patients with node-recurrence esophageal cancer after radical surgery |
|
|
| Completed | 3 | 120 | | single intensity-modulated radiotherapy ;concurrent DDP/5FU chemoradiotherapy | Anyang Tomour Hospital; Anyang Tomour Hospital, self finance | esophageal cancer | | | | |
2013-003244-23: Study evaluating, as first-line treatment of metastatic colorectal cancer, Bevacizumab +FOLFIRI followed by Bevacizumab + FOLFOX( or XELOX) or the reverse sequence Bevacizumab + FOLFOX (or XELOX) folloewed by Bevacizumab + FOLFIRI versus the standard Bevacizumab+ FOLFIRI Studio che mette a confronto, come trattamento di prima linea del tumore metastatico del colon-retto, il Bevacizumab + FOLFIRI seguito da Bevacizumab + FOLFOX (o XELOX) oppure la squenza inversa Bevacizumab + FOLFOX ( o XELOX) seguito da Bevacizumab + FOLFIRI contro la terapia standard che prevde Bevacizumab + FOLFIRI. |
|
|
| Ongoing | 3 | 400 | Europe | Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Powder for infusion, Avastin, CAMPTO, OXALIPLATINO, XELODA, FLUOROURACILE TEVA, LEVOFOLENE | S.I.C.O.G. ONLUS, S.I.C.O.G. ONLUS | Unresectable and metastatic colorectal cancer carcinoma del colon-retto inoperabile e metastatico, Advanced tumour of colon/rectum Tumore avanzato del colon-retto, Diseases [C] - Cancer [C04] | | | | |
2014-004436-19: Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment line Studio di fase III per confrontare due diversi trattamenti chemioterapici per valutare se la prima linea con tre farmaci + bevacizumab seguita da una seconda linea con lo stesso schema terapeutico possa fornire risultati migliori rispetto a un trattamento con due farmaci + bevacizumab sia nella prima che nella seconda linea di trattamento |
|
|
| Ongoing | 3 | 654 | Europe | Bevacizumab, 5 Fluorouracile, Irinotecan, Oxaliplatino, acido levo-folinico (L-Leucovorin), Bevacizumab, 5 Fluorouracile, Irinotecan, Oxaliplatino, acido levo-folinico (L-Leucovorin), Concentrate for solution for infusion, Solution for infusion, Powder for solution for infusion, Avastin, FLUOROURACILE TEVA* 500mg/10 ml, IRINOTECAN TEVA* 20 mg/ml, OXALIPLATINO TEVA* 5 mg/ml, LEDERFOLIN PFIZER* 25 mg | G.O.N.O., Roche S.p.A. | METASTATIC COLORECTAL CANCER Carcinoma colorettale metastatico (mCRC), metastatic tumor of colon-rectum, Diseases [C] - Cancer [C04] | | | | |
2013-004307-39: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer |
|
|
| Ongoing | 3 | 1050 | Europe | 5-fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, 5-fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel, Trastuzumab, Infusion, Solution for injection in cartridge, | University of Birmingham, Cancer Research UK, Celgene | Breast cancer, Breast cancer, Diseases [C] - Cancer [C04] | | | | |
2013-003047-29: BALLAD UK- a trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma |
|
|
| Ongoing | 3 | 120 | Europe | Fluorouracil, Folinic Acid, Capecitabine, Oxaliplatin, Solution for injection/infusion, Film-coated tablet, Solution for infusion | Greater Glasgow and Clyde Health Board, University of Glasgow, CRUK | Small Bowel Adenocarcinoma, Small Bowel Adenocarcinoma, Diseases [C] - Cancer [C04] | | | | |
2014-005188-34: Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherapy. Etude de phase III de préservation laryngée comparant une Chimiothérapie première suivie de Radiothérapie à une chimiothérapie administrée pendant la radiothérapie. |
|
|
| Not yet recruiting | 3 | 440 | Europe | CISPLATINE, DOCETAXEL, Fluorouracile, DOCETAXEL, Solution for infusion, Cisplatine Accord, Docetaxel Accord, Fluorouracile, CISPLATINE ACCORD | GORTEC, GORTEC | carcinomes épidermoïdes du larynx ou de l’hypopharynx localement avancé, carcinomes épidermoïdes du larynx ou de l’hypopharynx localement avancé, Diseases [C] - Cancer [C04] | | | | |
2004-000329-31: Continuous fluorouracil plus mitomycin C versus mitomycin C plus Cisplatin as chemotherapy combination in combined radiochemotherapy for locally advanced anal cancer. A phase II-III study |
|
|
| Ongoing | 3 | 50 | Europe | MITOMYCIN C*INIET 1FL 40MG, CISPLATINO MAYNE*EV 100MG100ML, MITOMYCIN C*INIET 1FL 40MG, CISPLATINO MAYNE*EV 100MG100ML | E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER | Locally Advanced Anal Cancer | | | | |
2005-000686-19: PACT (Patient Preferences in Adjuvant Colorectal Cancer Therapy) - A randomised crossover clinical trial comparing Bolus Fluorouracil/Leucovorin to Capecitabine as treatment for moderate to high risk resected colorectal cancer |
|
|
| Ongoing | 3 | 74 | Europe | Xeloda, Xeloda, 5-fluorouracil, Leucovorin, Xeloda, 5-fluorouracil, Leucovorin | University of Leeds | Moderate to high risk resected colorectal cancer | | | | |
2007-003810-32: Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. |
|
|
| Ongoing | 3 | 120 | Europe | Fluorouracil, Tamoxifen, Docetaxel, Epirubicin, Paclitaxel, Cyclophosphamide, Doxorubicin, Methotrexate, Anastrozole, Letrozole, Exemestane, Chemotherapy, Hormone Therapy, Chemotherapy, Hormone Therapy | the All-Ireland cooperative oncology research group (ICORG) | Patients will be ER and/or PR-positive, axillary node negative, HER2 negative breast cancer patients. | | | | |
2007-001530-14: Essai de Phase III, Multicentrique, Randomisé, comparant la Chimiothérapie d’induction par Docétaxel, Cisplatine et 5-Fluorouracile (TPF) suivie d’une chimio-radiothérapie concomitante versus une chimio-radiothérapie concomitante seule, dans les cancers du nasopharynx classés T2b, T3, T4 et/ou avec envahissement ganglionnaire (>> N1) |
|
|
| Ongoing | 3 | 30 | Europe | TAXOTERE 80 mg TAXOTERE 20 mg | GORTEC, | Patients atteints de cancers du nasopharynx classés T2b; T3;T4 ; OMS II-III et /ou avec envahissement ganglionnaire (Nsupérieur ou égal à 1) | | | | |
2008-005760-14: Etude de phase III randomisée, multicentrique comparant une chimiothérapie d’induction par TPF suivie d’une association radiothérapie Erbitux® versus une radiochimiothérapie concomitante chez des patients présentant un carcinome épidermoïde des VADS localement évolué inopérable |
|
|
| Ongoing | 3 | 284 | Europe | CETUXIMAB, Cisplatine, TAXOTERE 80mg, fluorouracile, LO1XC06, DOCETAXEL, 5FU, ERBITUX, CISPLATINE IBD3 PHARMA CONSULTING, TAXOTERE 80mg, FLUOROURACILE DAKOTA, ERBITUX, CISPLATINE IBD3 PHARMA CONSULTING, TAXOTERE 80mg, FLUOROURACILE DAKOTA | GORTEC | Cet essai sera proposé aux patients porteurs de carcinome épidermoïde histologiquement prouvé de la cavité buccale, de l\'oropharynx, du larynx, ou de l\'hypopharynx, de stadeIV non métastatique (carcinome localement évolué inopérable). | | | | |
2011-001858-28: A clinical trial for people who have cancer of the food pipe and junction of the food pipe and stomach, to compare chemotherapy before and after surgery, with chemotherapy with radiotherapy before surgery. |
|
|
| Ongoing | 3 | 378 | Europe | Epirubicin, Cisplatin, 5 Fluorouracil, Capecitabine, Paclitaxel, Carboplatin, Oxaliplatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin | ICORG, ICORG- All Ireland Cooperative Oncology Research Group, ICORG, | Adenocarcinoma of the oesophagus and oesophago-gastric junction | | | | |
| Recruiting | 3 | 300 | | Maintain with capecitabine after XELOX or FOLFOX treatment ;XELOX or FOLFOX | West China Hospital，Sichuan University; West China Hospital，Sichuan University, No-funds | advanced colorectal cancer | | | | |
2005-000838-21: RANDOMIZED STUDY OFRADIOTHERAPY WITH CONCOMITANT BOOST (RTcb) AND CONCURRENT LOW DOSE CISPLATINVSRTcb AND CISPLATIN + FLUOROURACILIN ADVANCED HNSCC |
|
|
| Ongoing | 3 | 344 | Europe | Solution for infusion | ISTITUTO NAZIONALE PER LA CURA TUMORI | Head and neck cancer | | | | |
NCT02265692: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer |
|
|
| Recruiting | 3 | 253 | US, Canada, RoW | therapeutic conventional surgery, cisplatin, CACP, CDDP, CPDD, DDP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, doxorubicin hydrochloride, ADM, ADR, Adria, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, liver transplantation, laboratory biomarker analysis | National Cancer Institute (NCI) | Childhood Hepatoblastoma, Stage I Childhood Liver Cancer, Stage II Childhood Liver Cancer, Stage III Childhood Liver Cancer, Stage IV Childhood Liver Cancer | 06/16 | | | |
2016-001783-12: Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial Valutazione della terapia di mantenimento con paclitaxel e ramucirumab a confronto con la prosecuzione della prima linea di trattamento in pazienti con carcinoma gastrico o della giunzione gastroesofagea avanzato ed HER-2 negativo |
|
|
| Ongoing | 3 | 280 | Europe | CYRAMZA, PACLITAXEL, OXALIPLATINO, Levofolene, LEVOFOLENE, FLUORURACILE AHCL, FLUOROURACILE AHCL, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 1, [-], Concentrate for solution for infusion, Powder for solution for injection, Solution for infusion, Film-coated tablet, CYRAMZA, PACLITAXEL MYLAN GENERICS - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 16.7 ML, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 20 ML, LEVOFOLENE - 175 MG POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO, FLUOROURACILE AHCL - 50MG/ML SOLUZIONE INIETTABILE O INFUSIONE 1 FLACONCINO IN VETRO DA 100 ML, CAPECITABINA ACCORD - 500 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/PVDC/ALU) - 120 COMPRESSE | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Eli Lilly Italia S.p.A | advanced HER-2 negative gastric or gastroesophageal junction cancers Carcinoma gastrico o della giunzione gastroesofagea avanzato ed HER-2 negativo, advanced HER-2 negative gastric or gastroesophageal junction cancers Carcinoma gastrico o della giunzione gastroesofagea avanzato ed HER-2 negativo, Diseases [C] - Cancer [C04] | | | | |
2016-002331-16: Comparaison d'un traitement par FOLFOX (Oxaliplatine et 5 FU) et du traitement par TFOX (oxaliplatine + 5 FU et Docetaxel) chez les patients ayant un cancer de l'estomac ou de la jonction entre estomac et oesophage localement avancé ou métastatique |
|
|
| Not yet recruiting | 3 | 506 | Europe | Solution for infusion, TAXOTERE | Fédération Francophone de Cancérologie Digestive, Fédération Francophone de Cancérologie Digestive | Cancer de l'estomac et de la jonction oeso-gastrique localement avancé ou métastatique, Patient présentant un cancer de l'estomac ou de la jonction estomac-oesophage localement avancé ou avec des métastases, Diseases [C] - Cancer [C04] | | | | |
APHINITY, NCT01358877 / 2010-022902-41: A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer |
|
|
| Active, not recruiting | 3 | 4804 | Europe, Canada, Japan, US, RoW | 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Perjeta®, Placebo, Trastuzumab, Herceptin® | Hoffmann-La Roche, Genentech, Inc., Breast International Group | Breast Cancer | 12/16 | 11/24 | | |
|
|
|
|
|
2016-004394-40: FOLFOXIRI plus Panitumumab or FOLFOX plus Panitumumab in the treatment of metastatic colorectal cancer. folfoxiri più panitumumab contro folfox più panitumumab nel carcinoma del colonretto metastatico. |
|
|
| Ongoing | 3 | 432 | Europe | Panitumumab, Fluorouracile, Oxaliplatino, Calcio Levofolinato, Irinotecan, [Panitumumab], [Fluorouracile], [Oxaliplatino], [Calcio Levofolinato], [Irinotecan], Solution for infusion, VECTIBIX - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 20 ML, FLUOROURACILE AHCL - 50MG/ML SOLUZIONE INIETTABILE O INFUSIONE 1 FLACONCINO IN VETRO DA 100 ML, OXALIPLATINO ACCORD - 5 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 40 ML, CALCIO LEVOFOLINATO TEVA - 25 MG POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, IRINOTECAN CSC - 20 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML | Fondazione GONO, Amgen, G.O.N.O. | Metastatic Colorectal Cancer Carcinoma Colorettale metastatico, colorectal cancer spread at distance tumore al colon retto diffuso a distanza, Diseases [C] - Cancer [C04] | | | | |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
2017-002036-17: The (cost)effectiveness of preoperative chemotherapy versus preoperative gemcitabine based chemoradiotherapy and adjuvant gemcitabine in patients with pancreatic cancer. |
|
|
| Ongoing | 3 | 368 | Europe | Leucovorin calcium, Fluorouracil, Irinotecan, Oxaliplatin, Powder for solution for injection/infusion, Solution for infusion, Concentrate for solution for infusion, LEUCOVORIN CALCIUM, Fluorouracil, Irinotecan, Oxaliplatin | Erasmus Medical Center, ZonMw, KWF | (borderline) resectable pancreatic cancer, (possible) resectable pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
2018-000377-68: Treatment for Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas |
|
|
| Ongoing | 3 | 218 | Europe | Paclitaxel in cationic liposomes, EndoTAG-1, Powder and solvent for concentrate for solution for infusion | SynCore Biotechnology Co., Ltd., SynCore Biotechnology Co., Ltd. | Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Unresectable Locally Advanced/ Metastatic Adenocarcinoma of the Pancreas, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 89 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, Epacadostat, INCB024360, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil | Incyte Corporation, Merck Sharp & Dohme LLC | Head and Neck Cancer | 07/18 | 12/24 | | |
2014-002517-39: Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more ETUDE DE PHASE III RANDOMISEE EVALUANT LA CHIMIOTHERAPIE ADJUVANTE APRES RESECTION D’UN ADENOCARCINOME COLIQUE DE STADE III CHEZ LES PATIENTS DE 70 ANS ET PLUS |
|
|
| Ongoing | 3 | 982 | Europe | Solution for infusion, Film-coated tablet, Fluorouracil Accord Healthcare 50 mg/ml, solution pour injection ou perfusion, Elvorine 25 mg/2,5 ml solution injectable Elvorine 50 mg/5 ml solution injectable, Xeloda 150 mg comprimés pelliculés. Xeloda 500 mg comprimés pelliculés., ELOXATIN 5 mg/ml solution à diluer pour perfusion | Fédération Francophone de Cancérologie Digestive (FFCD), FFCD itself, Belgian Group Digestive Oncology( BGDO) | Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over Traitement adjuvant d'un adénocarcinome colique de stade III totalement réséqué chez les patients de 70 ans et plus, Adjuvant treatment in stage III adenocarcinoma of the colon fully resected for patient of 70 years and over Traitement adjuvant d'un adénocarcinome colique de stade III totalement réséqué chez les patients de 70 ans et plus, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 437 | Europe | PTC+Pertuzumab, Paclitaxel; 80 mg/m2; day 1,8, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg); day 1, Carboplatin; AUC=6; day 1, Pertuzumab; 420 mg (loading dose 840 mg); day 1, FEC-T+Pertuzumab, Fluorouracil; 500 mg/m2; day 1, Epirubicine; 90 mg/m2; day 1, Cyclophosphamide 500 mg/m2; day 1, Trastuzumab; 6 mg/kg (loading dose 8 mg/kg) | The Netherlands Cancer Institute, Roche Pharma AG, Borstkanker Onderzoek Groep | Breast Cancer, HER2 Positive | 12/18 | 12/30 | | |
2018-002886-21: A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma. |
|
|
| Not yet recruiting | 3 | 210 | Europe | Powder for concentrate for solution for infusion, Concentrate for solution for infusion | UNICANCER, Programme hospitalier de recherche clinique (PHRC) | Metastatic Pancreatic Ductal Adenocarcinoma, Advanced pancreas cancer, Diseases [C] - Cancer [C04] | | | | |
2018-002833-39: A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment for locally recurrent rectal cancer (GRECCAR – PRODIGE – FRENCH) Etude randomisée de phase III comparant chimiothérapie suivie d’une ré-irradiation pelvienne versus chimiothérapie seule en traitement préopératoire des récidives locorégionales des cancers du rectum (GRECCAR-PRODIGE-FRENCH) |
|
|
| Not yet recruiting | 3 | 186 | Europe | CAPECITABINE, OXALIPLATINE, IRINOTECAN, ACIDE FOLINIQUE, 5-FU, Tablet, Concentrate for solution for infusion, Solution for injection, Solution for solution for injection, XELODA, ELOXATINE, CAMPTO, ELVORINE, FLUOROURACILE ACCORD | CHU DE BORDEAUX, Ministère de la santé | Recurrent rectal cancer after local excision Récidive loco-régionale d’un cancer du rectum, Rectal cancer Cancer du rectum, Diseases [C] - Cancer [C04] | | | | |
2018-002717-35: Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer |
|
|
| Not yet recruiting | 3 | 574 | Europe | OXALIPLATINE, irinotecan, fluorouracile, capecitabine, Concentrate for solution for infusion, Solution for injection, Solution for infusion, | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP), DGOS | Adults ≥ 18 years with middle or low locally advanced resectable rectal carcinoma, locally advanced resectable rectal cancer, Diseases [C] - Cancer [C04] | | | | |
2018-002831-65: BALLAD BELGIUM: A trial to evaluate the potential benefit of adjuvant chemotherapy, that means a chemotherapy in addition to the curative surgery for small bowel adenocarcinoma |
|
|
| Ongoing | 3 | 30 | Europe | Solution for infusion, Film-coated tablet, Fluorouracil Accord Healthcare 50 mg/ml, solution pour injection ou perfusion, Elvorine 25 mg/2,5 ml solution injectable Elvorine 50 mg/5 ml solution injectable, Xeloda 150 mg comprimés pelliculés, Xeloda 500 mg comprimés pelliculés, ELOXATIN 5 mg/ml solution à diluer pour perfusion | Belgian Group of Digestive Oncology (BGDO), Belgian Group of Digestive Oncology (BGDO) | small bowel adenocarcinoma, SMALL BOWEL ADENOCARCINOMA, Diseases [C] - Cancer [C04] | | | | |
PRODIGY, NCT01515748: Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer |
|
|
| Completed | 3 | 530 | RoW | Docetaxel (XRP6976), Oxaliplatin (SR96669), S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil) | Sanofi | Gastric Cancer | 01/19 | 12/21 | | |
| Completed | 3 | 882 | NA | Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, Carboplatin, 5-FU, Cetuximab | Merck Sharp & Dohme LLC | Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | 02/19 | 07/23 | | |
|
|
|
|
PRODIGE 23, NCT01804790: Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer |
|
|
| Active, not recruiting | 3 | 461 | Europe | mFolfirinox, Radiotherapy 50 Gy, Capecitabine, TME surgery, mFolfox6 or capecitabine | UNICANCER | Cancer of the Rectum | 09/19 | 05/25 | | |
2019-000935-15: CIRCULATE - A TRIAL TO IMPROVE CARE OF PATIENTS AFTER COLON TUMOR SURGERY, BASED ON AN INNOVATIVE MARKER: CIRCULATING TUMOR DNA CIRCULATE - un essai visant à améliorer la prise en charge des patients opérés de leur tumeur colique, basé sur un nouveau marqueur : l'ADN tumoral circulant |
|
|
| Not yet recruiting | 3 | 1980 | Europe | Solution for infusion, Fluorouracile Ebewe, Eloxatine | Centre Hospitalier Universitaire (CHU) de Dijon, INCA-PHRC | stage II colon cancer, after tumour resection cancer du colon de stade II, après résection de la tumeur, patient with early care of their colon cancer, after complete surgery of the tumour, Diseases [C] - Cancer [C04] | | | | |
2019-001364-30: Randomized phase 3 trial comparing FOLFOX to gemcitabine in metastatic first-line in patients with pancreatic adenocarcinoma and non-fit for FOLFIRINOX |
|
|
| Not yet recruiting | 3 | 400 | Europe | Oxaliplatin, Folinic acid, 5-Fluorouracil, Gemcitabine, Solution for infusion, Powder for solution for infusion | Assistance Publique- Hôpitaux de Paris | Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 2000 | Europe | FOLFOX regimen, folinic acid, infusional fluorouracil, and oxaliplatin, CAPOX, capecitabine plus oxaliplatin; XELOX | GERCOR - Multidisciplinary Oncology Cooperative Group | Colorectal Cancer | 01/20 | 12/23 | | |
2018-001728-20: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ). Neoadjuvante Radiochemotherapie versus Chemotherapie für Patienten mit lokal fortgeschrittenem, potentiell resektablen Adenokarzinom des ösophagogastralen Übergangs. |
|
|
| Not yet recruiting | 3 | 340 | Europe | 5-Fluorouracil, Calcium Folinate, Oxaliplatin, Docetaxel, Solution for injection, Solution for solution for injection | Ruprecht-Karls-Universität Heidelberg, Deutsche Krebshilfe | Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ), Locally advanced resectable gastric cancer, Diseases [C] - Cancer [C04] | | | | |
2018-000876-14: ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients A randomized phase III trial of the German Rectal Cancer Study Group |
|
|
| Not yet recruiting | 3 | 702 | Europe | 5-fluorouracil, Oxaliplatin, Capecitabine, folinic acid, Solution for infusion, Concentrate for solution for infusion, Tablet | University Hospital Frankfurt, Goethe University, German Cancer Aid | Locally advanced rectal cancer (UICC stage II and III), Rectal cancer, Diseases [C] - Cancer [C04] | | | | |
2019-000698-22: Olaparib +/- bevacizumab in CRC with SD/PR/CR from FOLFOX with bevacizumab. |
|
|
| Ongoing | 3 | 525 | Europe | Olaparib, MK-7339, Film-coated tablet, Concentrate for solution for infusion, Solution for injection/infusion, Avastin (Bevacizumab), 5-Fluorouracil-Ebewe (5-FU) | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc | The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab, Advanced Metastatic Colorectal Cancer (Has not progressed after completing at least 6 prior induction cycles of FOLFOX + Bevacizumab and can no longer tolerate any components of FOLFOX), Diseases [C] - Cancer [C04] | | | | |
CALGB, NCT01150045: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery |
|
|
| Active, not recruiting | 3 | 2527 | Canada, US | celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 02/20 | | | |
| Active, not recruiting | 3 | 920 | Europe, US | M1 scheme, standard long course chemoradiotherapy | University Medical Center Groningen, Karolinska University Hospital, Leiden University Medical Center, Uppsala University Hospital, Dutch Cancer Society | Rectal Cancer | 03/20 | 12/26 | | |
NCT03511963: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC |
|
|
| Active, not recruiting | 3 | 677 | RoW | HLX04 100 mg in 4 ml Injection, Avastin 100 mg in 4 ml Injection | Shanghai Henlius Biotech | Metastatic Colorectal Cancer (mCRC) | 04/20 | 04/24 | | |
2020-000149-15: Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus. |
|
|
| Not yet recruiting | 3 | 1020 | Europe | Carboplatin, Paklitaxel, Cisplatin, 5-fluorouracil, Oxaliplatin, Calcium folinate, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for injection/infusion | Karolinska University Hospital, Karolinska University Hospital, Swedish Research Council | Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, Cancer in the gullet (esophagus), which is possible to operate., Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 3 | 2031 | Europe, Canada, Japan, US, RoW | Nivolumab, Opdivo, BMS-936558, Ipilimumab, Yervoy, BMS-734016, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma | 05/20 | 05/24 | | |
|
|
|
|
|
|
NCT02879513: Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy |
|
|
| Recruiting | 3 | 290 | RoW | Paclitaxel, Taxol, Cisplatin, Epirubicin, Cyclophosphamide, 5-fluoruracil, 5-FU | RenJi Hospital | Invasive Ductal Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Inflammatory Breast Cancer | 06/20 | 12/22 | | |
2015-004731-12: Prophylactic intraocular treatment with 5-FU and Heparin during surgery for retinal detachment in patients at high risk for postoperative scar formation (Proliferative Vitreoretinopathy) |
|
|
| Not yet recruiting | 3 | 560 | Europe | Dalteparin and 5FU in BSS, Irrigation solution | University of Cologne, Deutsche Forschungsgemeinschaft (DFG) | Primary rhegmatogenous retinal detachment (RRD) accompanied by elevated protein levels in anterior chamber fluid (laser flare value ≥15pc/ms)., Primary retinal detachment caused by retinal tear(s) combined with subclinical inflammatory conditions in the eye measured by laser flare photometry (laser flare value ≥15pc/ms), Diseases [C] - Eye Diseases [C11] | | | | |
| Completed | 3 | 749 | Europe, Canada, Japan, US, RoW | Pembrolizumab, MK-3475, Placebo, Cisplatin, 5-FU | Merck Sharp & Dohme LLC | Esophageal Neoplasms | 07/20 | 07/23 | | |
2020-002141-42: Addition of induction chemotherapy to the neoadjuvant treatment of patients with locally recurrent rectal cancer - the PelvEx II study Toevoeging van inductie chemotherapie aan de voorbehandeling van patiënten met lokaal teruggekeerde endeldarmkanker - de PelvEx II studie |
|
|
| Not yet recruiting | 3 | 364 | Europe | Capecitabine Accord, Oxaliplatin Accord, 5-Fluorouracil, Leucovorine Sandoz, Irinotecan, Infusion, Tablet, Oxaliplatin, Capecitabine, 5-fluorouracil, Leucovorin, Irinotecan | Catharina Hospital, Instituto Português de Oncologia de Lisboa Francisco Gentil – EPE, Catharina Ziekenhuis Eindhoven, ZonMW, ZonMw, Catharina Ziekenhuis Eindhoven | Locally recurrent rectal cancer Lokaal recidief rectum carcinoom, Locally recurrent rectal cancer Lokaal teruggekeerde endeldarmkanker, Diseases [C] - Cancer [C04] | | | | |
2020-000613-32: This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with a chemotherapy treatment for people with colorectal cancer after all available standard treatments. |
|
|
| Ongoing | 3 | 668 | Europe | Napabucasin, GB201, Capsule, Solution for injection, Solution for injection/infusion, Concentrate for solution for infusion, Bendafolin, 5-Flurouracil-Ebewe, Irinotecan Bendalis | 1Globe Health Institute, 1Globe Health Institute | Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic., Cancer of the colon or rectum., Diseases [C] - Cancer [C04] | | | | |
2017-003832-35: Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma – The phase III “PREVENT” trial of the AIO /CAOGI /ACO |
|
|
| Not yet recruiting | 3 | 200 | Europe | Docetaxel, Oxaliplatin, 5-fluorouracil, Leucovorin, Cisplatin, Concentrate for solution for infusion, Solution for injection | Institute of Clinical Cancer Research (IKF) Krankenhaus Nordwest, Deutsche Krebshilfe | locally advanced resectable diffuse type adenocarcinoma of the oesophagogastric junction or the stomach, locally advanced resectable diffuse type gastric cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900022288: Induction chemotherapy with GP versus TPF in III-IVA nasopharyngeal carcinoma: a randomized controlled trial |
|
|
| Not yet recruiting | 3 | 378 | | gemcitabine + cisplatin ;docetaxel + cisplatin + fluorouracil | West China Hospital, Sichuan University; West China Hospital, Sichuan University, West China Hospital, Sichuan University | nasopharyngeal carcinoma | | | | |
2018-001356-35: FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure |
|
|
| Not yet recruiting | 3 | 550 | Europe | 5-Fluorouracil, Oxaliplatin, Leucovorin, Capecitabin, Solution for injection, Concentrate and solvent for solution for infusion, Tablet, Oxaliplatin, Leucovorin, Capecitabin | University of Heidelberg, German Cancer Aid | Locally advanced rectal adenocarcinoma localized 0 - 16 cm from the anal verge with low risk of local failure, Locally advanced rectal cancer with low risk of local failure, Diseases [C] - Cancer [C04] | | | | |
NCT03415763: Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy |
|
|
| Recruiting | 3 | 764 | RoW | Capecitabine, Xeloda, mFOLFOX6 or CAPOX, 5-Fu-leucovorin-oxaliplatin or xeloda-oxaliplatin | LI XIN-XIANG | Rectal Neoplasms | 12/20 | 12/25 | | |
ChiCTR1900020790: A randomized, multicenter, phase III trial for apatinib combined with 5-fluorouracil (5-fu) and cisplatin versus 5-fluorouracil and cisplatin for the treatment of recurrent or metastatic nasopharyngeal carcinoma |
|
|
| Recruiting | 3 | 300 | | dosage regime:PF+Apatinib ;PF protocol | the First Affiliated Hospital of Guangxi Medical University; None, Provided by the first affiliated hospital of guangxi medical university | recurrent or metastatic nasopharyngeal carcinoma | | | | |
CheckMate 648, NCT03143153 / 2016-001514-20: A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin |
|
|
| Active, not recruiting | 3 | 970 | Europe, Canada, Japan, US, RoW | Nivolumab, BMS-936558 (Nivolumab), Opdivo (Nivolumab), Ipilimumab, BMS-734016 (Ipilimumab), Yervoy (Ipilimumab), Cisplatin, Fluorouracil | Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd | Various Advanced Cancer | 01/21 | 01/25 | | |
|
|
|
|
|
|
|
|
| Completed | 3 | 830 | Europe | Induction chemotherapy with gemcitabine or FOLFIRINOX, all brands of gemcitabine and FOLFIRINOX components are allowed, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine, all brands of gemcitabine are allowed, Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy | University of Erlangen-Nürnberg Medical School | Pancreatic Cancer | 02/21 | 11/23 | | |
KEYNOTE-177, NCT02563002 / 2015-002024-89: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/) |
|
|
| Completed | 3 | 307 | NA | mFOLFOX6, FOLFIRI, Pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®, Bevacizumab, Cetuximab | Merck Sharp & Dohme LLC | Colorectal Carcinoma | 02/21 | 07/23 | | |
|
|
|
|
|
ChiCTR1800015063: A randomized, parallel and multicenter study of the intervention effects of three chemotherapy regimens in patients with first-line metastatic esophageal squamous cell carcinoma |
|
|
| Recruiting | 3 | 1308 | | cisplatin plus 5- fluorouracil ;paclitaxel plus cisplatin ;paclitaxel plus nedaplatin | Nanyang Central Hospital, Henan; Nanyang Central Hospital, Henan, raise independently | metastatic esophageal squamous cell carcinoma | | | | |
2019-004582-40: TIming of start of systemIc treatment for asymptomatic MEtastasized PANcreatic cancer |
|
|
| Ongoing | 3 | 184 | Europe | Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, Paclitaxel, Gemcitabine, Concentrate for solution for infusion | Amsterdam UMC-Location AMC-dept. Internal Medicin, University of Amsterdam | Metastasized pancreatic cancer Gemetastaseerd pancreas carcinoom, Metastasized pancreatic cancer Uitgezaaide alvleesklierkanker, Diseases [C] - Cancer [C04] | | | | |
2020-005078-82: Phase III study in patients with colorectal cancer RAS/BRAF un mutated on the tumor tissue and RAS mutated in liquid biopsy with the aim of comparing a FOLFIRI therapy in combination with cetuximab or bevacizumab. Studio di fase III in pazienti con diagnosi di tumore del colon-retto in presenza di RAS/BRAF non mutato sul tessuto del tumore e RAS mutato sulla biopsia liquida con l'obiettivo di confrontare una terapia con schema FOLFIRI in associazione al farmaco cetuximab o bevacizumab. |
|
|
| Not yet recruiting | 3 | 280 | Europe | Cetuximab, BEVACIZUMAB, [Cetuximab], [BEVACIZUMAB], Solution for infusion, Concentrate for solution for infusion, Erbitux, AVASTIN | AZIENDA OSPEDALIERA ARCISPEDALE SANTA MARIA NUOVA/IRCCS DI REGGIO EMILIA, AIFA - Italian Medicines Agency | Patients with metastatic colorectal cancer RAS/BRAF wild type not previously treated in metastatic setting Pazienti con tumore del colon-retto metastatico (mCRC)RAS/BRAF wild type non precedentemente trattati per malattia metastatica., Patients with mestatic colorectal cancer diagnosis with RAS/BRAF not mutated and never treated for metastatic disease Pazienti con diagnosi di tumore metastatico al colon-retto con RAS/BRAF non mutato mai trattati precedentemente per malattia mestatica, Diseases [C] - Cancer [C04] | | | | |
2020-001001-22: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, unresctable ESCC |
|
|
| Not yet recruiting | 3 | 600 | Europe | Durvalumab, Cisplatin, capecitabine, 5-fluorouracil, MEDI4736, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Cisplatin NeoCorp® 1 mg/mL - concentrate for solution for infusion, Capecitabine (Capecitabin cell pharm® 150 mg and 500 mg film-coated tablets), 5-FU medac 50 mg/ml, solution for injection, Capecitabine Accord 150 mg and 500 mg film coated tablets, Cisplatin Teva® 1 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Benda-5 FU 50 mg/ml, solution for injection | AstraZeneca AB, AstraZeneca AB | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Specific type of Esophageal cancer called "Esophageal Squamous Cell Carcinoma" (ESCC) that cannot be removed by surgery, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-TRC-13003285: A Multicenter Phase III Trial of Induction Chemotherapy with 5-Fu and Loboplatin versus Cisplatin followed by Concurrent Chemoradiotherapy With Loboplatin versus Cisplatin and IMRT in Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Completed | 3 | 492 | | 1. Induction chemotherapy with Loboplatin and 5-FU (LF)(3 weekly), LBP 30mg/m2 d1; d22, 5-Fu 4g/m2 120hciv, d1-5; d22-26; 2. Concurrent chemoradiotherapy with Loboplatin and IMRT, LBP 30mg/m2, d43; d64; 3. Radical radiotherapy: after two periods of induction chemotherapy of LF. PTVnx: 68-70Gy/30-32f PTVnd: 62-68Gy/30-32f PTV1: 60-64Gy/30-32f PTV2: 54-58Gy/30-32f ;1. Induction chemotherapy with cisplatin and 5-FU (PF)(3 weekly), P 80mg/m2 d1; d22. 5-Fu 4g/m2 120hciv. d1-5; d22-26; 2. Concurrent chemoradiotherapy with cisplatin and IMRT, P 80mg/m2, d43; d64; 3. Radical radiotherapy: after two periods of induction chemotherapy of PF. PTVnx: 68-70Gy/30-32f PTVnd: 62-68Gy/30-32f PTV1: 60-64Gy/30-32f PTV2: 54-58Gy/30-32f | Sun Yat-sen University Cancer Centre; Sun Yat-sen University Cancer Centre, Hainan Chang'an International Pharmaceutical Co., Ltd. | Nasopharyngeal Carcinoma | | | | |
OPTICAL, NCT02572141: FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer |
|
|
| Active, not recruiting | 3 | 738 | RoW | Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens, Oxaliplatin, 5-Fluorouracil, Capecitabine, Leucovorin, Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens | Sun Yat-sen University | Colon Cancer | 04/21 | 04/23 | | |
| Active, not recruiting | 3 | 464 | Europe, RoW | FOLFIRI-cetuximab, mFOLFOX6-bevacizumab, OPTIMOX-bevacizumab, irinotecan-based chemo + bevacizumab, Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab), XELOX + bevacizumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Hoffmann-La Roche | Colorectal Cancer Metastatic | 07/23 | 12/24 | | |
2020-005141-16: Chemotherapy before or after surgery in patients with resectable pancreatic cancer: the PREOPANC-3 study. |
|
|
| Not yet recruiting | 3 | 378 | Europe | Leucovorin calcium, Fluorouracil, Irinotecan, Oxaliplatin, Powder for solution for injection/infusion, Solution for infusion, Concentrate for solution for infusion, LEUCOVORIN CALCIUM, Fluorouracil, Irinotecan, Oxaliplatin | Erasmus MC, Erasmus MC | non-metastatic resectable pancreatic cancer, non-metastatic resectable pancreatic cancer, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-IPR-15006378: Comparison the effects of different neoadjuvant chemotherapy regimen on acute toxicity, tumor response, and survival in patients with advanced nasopharyngeal carcinoma |
|
|
| Not yet recruiting | 3 | 108 | | cisplatin and 5-FU chemotherapy once a week ;Traditional PF chemotherapry once three week | Fujian Provincial Cancer Hospital; Fujian Provincial Cancer Hospital, the research funds | nasopharyngeal carcinoma | | | | |
2021-000317-17: Survival analysis after pre-surgical therapy in patients with resectable pancreatic cancer and risk factors ANÁLISIS DE SUPERVIVENCIA TRAS TRATAMIENTO ANTES DE LA CIRUGÍA EN CÁNCER DE PÁNCREAS RESECABLE CON FACTORES DE RIESGO |
|
|
| Ongoing | 3 | 116 | Europe | Irinotecan, Fluorouracil, Oxaliplatin, calcium folinate, Concentrate for solution for injection/infusion, Solution for infusion | Fundación para la Gestión de la Investigación Biomédica de Cádiz-INIBICA, Instituto de Salud Carlos III | Resectable pancreatic cancer and risk factors Cáncer de pancreas resecable con factores de riesgo, Non-operable pancreatic cancer plus other conditions that increase the possibility to adquire a disease Cancer de pancreas no operable mas otras condiciones que aumenten la posibilidad de adquirir una enfermedad, Diseases [C] - Cancer [C04] | | | | |
NCT02940925: TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma |
|
|
| Completed | 3 | 241 | RoW | Drug: Taxol,cisplatin and capecitabine, Drug: Cisplatin and 5-Fluorouracil | Sun Yat-sen University | Nasopharyngeal Carcinoma | 08/21 | 08/21 | | |
| Completed | 3 | 746 | Europe, US, RoW | Sintilimab, Cisplatin, Paclitaxel, Fluorouracil, Placebo | Innovent Biologics (Suzhou) Co. Ltd., Fortrea | Esophageal Squamous Cell Carcinoma | 09/21 | 07/23 | | |
|
2021-000830-33: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne La PIPAC (Pressurized intraperitoneal aerosol chemotherapy) nella terapia multimodale per pazienti con metastasi peritoneale limitata da cancro gastrico: studio sperimentale multicentrico randomizzato di fase III. PIPAC_VEROne |
|
|
| Not yet recruiting | 3 | 98 | Europe | Oxaliplatino, 5-Fluorouracile, Cisplatino, Doxorubicina, Acido folinico, [Oxaliplatino], [Fluorouracile], [Cisplatino], [Doxorubicina], [Calcio levofolinato], Concentrate for solution for injection/infusion, Solution for injection/infusion, Powder for solution for injection/infusion | AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA, Azienda Ospedaliera Universitaria Integrata Verona | Gastric adenocarcinoma with peritoneal metastases Adenocarcinoma gastrico con metastasi peritoneali, Gastric adenocarcinoma with peritoneal metastases Adenocarcinoma gastrico con metastasi peritoneali, Diseases [C] - Digestive System Diseases [C06] | | | | |
2020-006144-18: Prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer Prospektive, randomisierte, offene, multizentrische Phase III Studie zur Untersuchung der Wirksamkeit einer Therapie in Patienten mit metastasiertem kolorektalen Karzinom, nach erfolgter Resektion oder Ablation |
|
|
| Not yet recruiting | 3 | 507 | Europe | 5-Fluorouracil, Oxaliplatin, Leucovorin, Irinotecan, Solution for solution for injection, Concentrate and solvent for solution for infusion, Solution for injection, Concentrate for solution for infusion, Oxaliplatin, Leucovorin | Charité Universitätsmedizin Berlin, DFG - Deutsche Forschungsgemeinschaft e.V. | Metastatic colorectal cancer after definite interventional therapy of all lesions, Metastatic colorectal cancer after therapy of lesions, Diseases [C] - Cancer [C04] | | | | |
2020-004906-79: A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma Studie zur Wirksamkeit einer Chemotherapie nach Operation beim Karzinom der Bauchspeicheldrüse, wobei die Zuteilung zur Oxaliplatin-basierten oder Gemcitabin-basierten Chemotherapie entweder nach klinischen Standardkriterien oder nach genetischen Markern erfolgt |
|
|
| Not yet recruiting | 3 | 394 | Europe | Gemcitabine, Capecitabine, 5-fluorouracil, Irinotecan, Calcium Folinate, Oxaliplatin, Powder for solution for infusion, Film-coated tablet, Solution for injection, Concentrate for solution for infusion, Solution for injection/infusion | Ruprecht-Karls-University Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg, Dietmar Hopp Stiftung, Cancerforskningsfonden i Norrland | Resected pancreatic ductal adenocarcinoma operiertes duktales Pankreas-Adenokarzinom, Resected pancreatic ductal adenocarcinoma operiertes duktales Bauchspeicheldrüsen-Adenokarzinom, Diseases [C] - Cancer [C04] | | | | |
APEC, NCT02965248: Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer ( Study) |
|
|
| Recruiting | 3 | 147 | RoW | Standard adjuvant systemic chemotherapy, adjuvant oxaliplatin, 5-FU, and leucovorin calcium (mFOLFOX6), adjuvant oxaliplatin and capecitabine (CapeOx), adjuvant 5-FU and leucovorin calcium (sLV5FU2), adjuvant capecitabine (Cape), Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed, Intraperitoneal raltitrexed 3 mg/m2, Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin, I.V. leucovorin calcium 20 mg/m2, I.V. 5-FU 400 mg/m2, Intraperitoneal oxaliplatin 130 mg/m2 | Fudan University | Locally Advanced Colorectal Cancer | 11/21 | 11/23 | | |
NCT05074589: Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer |
|
|
| Completed | 3 | 298 | RoW | Irinotecan liposome、5-Fluorouracil、Leucovorin, Placebo、5-Fluorouracil、Leucovorin | Jiangsu HengRui Medicine Co., Ltd. | Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy | 11/21 | 03/22 | | |
NCT02087475: Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin |
|
|
| Recruiting | 3 | 360 | RoW | Irinotecan, 5-fluorouracil, Local radiotherapy, R0 resection | Sixth Affiliated Hospital, Sun Yat-sen University | Colorectal Neoplasms, Effects of Chemotherapy, Surgery, Metastasis, Local Neoplasm Recurrence | 12/21 | 12/24 | | |
ARMANI, NCT02934464: Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers |
|
|
| Recruiting | 3 | 280 | Europe | RAMUCIRUMAB, Cyramza, Paclitaxel, FOLFOX 4, Oxaliplatino + l-leucovorin + 5 Fluorouracile, mFOLFOX 6, XELOX, Oxaliplatino + Capecitabina | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Stomach Neoplasms | 12/21 | 12/21 | | |
NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer |
|
|
| Recruiting | 3 | 600 | RoW | POF, CAPOX/SOX/FOLFOX | Fujian Cancer Hospital | Gastric Cancer Stage III | 12/21 | 12/23 | | |
NCT04303429: Adjuvant Chemotherapy in High Risk Stage II Colon Cancer |
|
|
| Not yet recruiting | 3 | 962 | NA | FOLFOX/XELOX/Capecitabine | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Stage II Colon Cancer, Adjuvant Chemotherapy | 01/22 | 01/25 | | |
| Active, not recruiting | 3 | 649 | Europe, Japan, US, RoW | Cisplatin, Oxaliplatin, Fluorouracil (5-FU), Capecitabine, Paclitaxel, Tislelizumab, BGB-A317, Placebo | BeiGene | Esophageal Squamous Cell Carcinoma (ESCC) | 02/22 | 08/24 | | |
|
|
|
ChiCTR2000037406: A prospective, randomized, controlled trial comparing adjuvant therapy after hepatectomy and pure hepatectomy in colorectal cancer liver metastasis patients with low-risk of recurrence |
|
|
| Not yet recruiting | 3 | 546 | | Adjuvant chemotherapy FOLFOX, CapeOX, or Xeloda single drug ;none | Shanghai Cancer Center, Fudan University; shanghai Cancer Center, Fudan University, none | colorectal cancer liver metastasis | | | | |
NCT04414566: Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 3 | 562 | RoW | gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil, GP;TPF, IMRT, IMRT and concurrent cisplatin | West China Hospital | Nasopharyngeal Carcinoma | 05/22 | 05/25 | | |
CAIRO4, NCT01606098: The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer |
|
|
| Completed | 3 | 206 | Europe | Surgery of the primary tumour, Systemic treatment, Bevacizumab in combination with fluoropyrimidine-based schedules | Dutch Colorectal Cancer Group, Hoffmann-La Roche | Colon Cancer, Primary Tumour, Rectal Cancer | 06/22 | 12/22 | | |
GRECCAR12, NCT02514278: Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy |
|
|
| Active, not recruiting | 3 | 218 | Europe | Neoadjuvant chemotherapy Folfirinox, 4 cycles, 50 Gy, 2 Gy/session; 25 fractions, Local excision in good responders, Rectal excision in bad responders, Capecitabine | University Hospital, Bordeaux | Rectal Cancer | 06/22 | 06/24 | | |
NAPOLI-3, NCT04083235 / 2018-003585-14: A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment |
|
|
| Active, not recruiting | 3 | 770 | Europe, Canada, US, RoW | Irinotecan Liposomal Injection, Onivyde®, Nal-IRI, Oxaliplatin, Eloxatin®, 5Fluorouracil, Adrucil®, flurouracil, 5-FU, Leucovorin, Folinic Acid, Nab-paclitaxel, Abraxane®, Gemcitabine, Gemzar® | Ipsen | Metastatic Adenocarcinoma of the Pancreas | 07/22 | 12/24 | | |
| Recruiting | 3 | 564 | Europe | FOLFOX/ FOLFIRI with bevacizumab, - bevacizumab, - irinotecan, - leucovorin, - 5-fluorouracil, - oxaliplatin, FOLFOXIRI with bevacizumab, FOLFOX/ FOLFIRI with panitumumab, - panitumumab | Dutch Colorectal Cancer Group | Colorectal Cancer, Liver Metastases | 08/22 | 07/25 | | |
KL140-Ⅲ-02-CTP, NCT04835142: Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC |
|
|
| Recruiting | 3 | 686 | RoW | Double blind control period A140, KL-140, Open single period A140 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Metastatic Colorectal Cancer | 08/22 | 04/23 | | |
NCT03851913: The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Beyond Milan Criteria BCLC Stage A/B Hepatocellular Carcinoma Who Underwent Hepatectomy |
|
|
| Recruiting | 3 | 344 | RoW | TAI | Sun Yat-sen University | Hepatocellular Carcinoma | 08/22 | 08/24 | | |
